FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
16.0 puan (24s)JeopolitikOne-OffHealth & Medicine3ay
KalshiKullanılabilirliği kontrol etKYC gerekli%2 ücretDoğrulanmış sonuçlanma verisiOrta düzey kalibreGüncel ima edilen olasılık
Evet 98%+16.0pt
Piyasa kalitesi
44 / 100
Düşük kalite24s Hacim
₺28,8 B
Likidite
₺8,8 B
Düşük likiditeAlış / Satış
80.0% / 88.0%
Spread
8.0 pt
Geniş spreadPiyasa verileri
4 dakika önce güncellendi
17 Haz 26 21:00 UTC1 Oca 27 04:59 UTC
Trendler
İlgili Piyasalar
Bağlam için ilgili sorular; eşdeğer sözleşmelerin karşılaştırması değildir.
FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
KalshiFDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
KalshiFDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)
KalshiDid COVID-19 come from a laboratory?
Manifold MarketsWhich states will report local cases in the May 2026 Ebola Bundibugyo outbreak
Manifold MarketsWhen, where or how will Trump die?
Manifold MarketsKurallar
If the FDA's decision on Ifinatamab Deruxtecan by Daiichi Sankyo in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
Uzlaşma kaynağı:AppliedXL
- This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
- Ifinatamab deruxtecan (also called I-DXd or DS-7300) is an antibody-drug conjugate — think of it as a guided missile where a targeting protein is chemically linked to a potent cancer-killing payload.
- The targeting protein homes in on a molecule called B7-H3 (also known as CD276), which appears in unusually high amounts on the surface of many cancer cells, and once the drug locks onto that target it is pulled inside the cell and releases its toxic payload.
- In doing so, it aims to kill tumor cells more precisely than traditional chemotherapy, which attacks both healthy and cancerous cells indiscriminately.
Açık piyasalar
Geopolitics
POLYMARKETWhich party will gain most seats in Russian Parliamentary Election?
- United Russia (ER)+4.0pt74%
- New People (NL)-3.3pt22%
- Liberal Democratic Party of Russia (LDPR)-1.0pt3%
+5 daha fazla sonuç
- Toplam Hacim
- ₺1,3 Mr
- 24s Hacim
- ₺29,5 Mn
POLYMARKETUS announces end of Iranian blockade by which date?
- December 31-3.9pt47.8%
- October 31-3.0pt29.2%
- September 30-4.0pt12.4%
+17 daha fazla sonuç
POLYMARKETUS x Iran Effective Ceasefire begins by...? (2 week pause)
- September 30-5.0pt74%
- September 18-10.0pt67%
- September 11-2.5pt63%
+2 daha fazla sonuç
POLYMARKETKharg Island no longer under Iranian control by which date?
- December 317%
- September 30+0.3pt1%
- July 310%
+7 daha fazla sonuç
- Toplam Hacim
POLYMARKETIsrael x Iran ceasefire continues through which date?
- July 18+0.3pt100%
- July 20+0.1pt100%
- July 22+0.5pt100%
+20 daha fazla sonuç
POLYMARKETWill China invade Taiwan by end of 2026?
- No-0.1pt96%
- Yes+0.1pt4%
- Toplam Hacim
- ₺2 Mr
- 24s Hacim
- ₺5,3 Mn
- Will the U.S. invade Iran before 2027?
- Nobel Peace Prize Winner 2026
- US-Iran nuclear deal?
- Russia x Ukraine peace talks by which date?
- Strait of Hormuz traffic returns to normal by December 31?
- Russia x Ukraine ceasefire agreement by which date?
- Bab el-Mandeb Strait effectively closed by which date?
- Iran full airspace closure by which date?
- Will the Iranian regime fall by September 30?
- Iran-Oman Hormuz Management Agreement by which date?
Sık sorulan sorular
- FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026) için güncel oranlar nedir?
- Kalshi, 8 Eylül 2026 itibarıyla Yes için 98% fiyatlıyor.
- FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026) ne zaman sonuçlanacak?
- FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026) için öngörülen sonuçlanma tarihi 1 Ocak 2027.
- FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026) nasıl sonuçlandırılıyor?
- Kalshi bu piyasayı şu şekilde sonuçlandırır: If the FDA's decision on Ifinatamab Deruxtecan by Daiichi Sankyo in 2026 is a full approval or an accelerated approval, the market resolves to Yes.